Celebrity Inventors
Comic actor Danny Kaye received patent D166,807 for the co-design of "Blowout Toy or the Like". It's similar to one of those toys that unravels when you blow into at a birthday party except Kaye's has three blowouts going in different directions, not just one.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7932420 | Sulfonamides The present invention provides wherein R1 is selected from the group consisting of C1-C10 alkoxy, OH and NR4R5; R2 is selected from the group... | 04/26/2011 |
| 7683211 | Jasmonate derivative compounds pharmaceutical compounds and methods of use thereof The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of ca... | 03/23/2010 |
| 7491844 | Therapeutic cyclopentane derivatives Described herein are compounds having a formula and therapeutic methods, compositions, and medicaments, related thereto. ... | 02/17/2009 |
| 7459583 | Method for providing a cathartic effect The present invention relates to a novel method for providing a cathartic effort to a patient in need of cathartic induction, which comprises administering to the patient a cathartic-inducing effective amount of halogenated bioactive lipid comprising the following p... | 12/02/2008 |
| 7425651 | Jasmonate derivative compounds, pharmaceuticals compounds and methods of use thereof The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of ca... | 09/16/2008 |
| 7396946 | Compound for treatment of external secretion disorders Disclosed is a method for treatment of external secretion disorders, which comprises administering a fatty 5 acid derivative to a subject in need of said treatment. The method of the present invention is useful for treatment of at least one condition selected from h... | 07/08/2008 |
| 7321057 | Method for manufacturing prostaglandin analogue The present invention provides a new method for manufacturing a prostaglandin analogue having one or more keto groups on the 5-membered ring and/or omega chain, which comprises the step of treating a corresponding hydroxyl group containing compound with a co-oxidize... | 01/22/2008 |
| 7314890 | Sulfonamides The present invention provides wherein R1 is selected from the group consisting of C1-C10 alkoxy, OH and NR4R5; R2 | 01/01/2008 |
| 7179937 | Cyclopentenone derivatives for cancer therapy The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of deriv... | 02/20/2007 |
| 7173151 | Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, i... | 02/06/2007 |
| 7141606 | Gabapentin analogues for sleep disorders The invention provides a new use of compounds for formula 1 or 1A or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of insomnia and related disorders. ... | 11/28/2006 |
| 7091231 | 12-Aryl prostaglandin analogs Compounds comprising are disclosed, wherein Y, A, X, R, D, and n are as described. A compound comprising a prostaglandin EP2 selective agonist wherein the ω-chain comprises a substituted pheny... | 08/15/2006 |
| 7071355 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents The present invention relates to compounds of the general formula (I) and salt and physiologically functional derivatives thereof, wherein A is a non-aromatic ring system... | 07/04/2006 |
| 6956056 | Method for providing a cathartic effect The present invention relates to a novel method for providing a cathartic effect to a patient in need of cathartic induction, which comprises administering to the patient a cathartic-inducing effective amount of halogenated bioactive lipid comprising the following p... | 10/18/2005 |
| 6909014 | Intermediates for the synthesis of ether compounds The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a compo... | 06/21/2005 |
| 6878723 | LTA4 hydrolase inhibitors The invention concerns compounds inhibiting LTA4 hydrolase of formula (I). The invention also concerns their therapeutic, in particular anti-inflammatory, applications. ... | 04/12/2005 |
| 6864390 | Method for the stereoselective synthesis of cyclic amino acids The instant invention is a route to stereospecific 3-substituted 5-membered ring isomers of Formula (A). The final products are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression,... | 03/08/2005 |
| 6740772 | Prostaglandin derivatives A prostaglandin derivative represented by the formula: wherein X is a halogen atom in the α- or β-position, Y is an ethylene group, a vinylene group or an ethynylene group, A is a group represented by the formul... | 05/25/2004 |
| 6689906 | Bicyclic amino acids as pharmaceutical agents The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritabl... | 02/10/2004 |
| 6680339 | 15-fluoro prostaglandins as ocular hypotensives 15-fluoro substituted analogs of PGF2 and methods of their use in treating glaucoma and ocular hypertension are disclosed.... | 01/20/2004 |
| 6667284 | Lubricant for magnetic recording medium and use thereof A magnetic recording medium and method for forming the magnetic recording medium are described. The magnetic recording medium includes a magnetic layer formed on a non-magnetic support, and a lubricant layer over the magnetic layer. The lubricant layer in... | 12/23/2003 |
| 6649653 | 15-fluoro prostaglandins as ocular hypotensives 15-Fluoro substituted analogs of PGF2 and methods of their use in treating glaucoma and ocular hypertension are disclosed.... | 11/18/2003 |
| 6642274 | Methods and compositions for preventing and treating prostate disorders The present invention relates to methods, compositions, devices and kits for the prevention and treatment of prostate disorders in mammals, including, but not limited to, benign prostatic hypertrophy, carcinoma of the prostate, prostadynia, prostatitis, a... | 11/04/2003 |
| 6576663 | 6-Keto prostaglandin F1 and analogs for treating dry eye Compositions and methods for the treatment of dry eye and related diseases utilizing 6-keto-PGF1 and its analogs are disclosed.... | 06/10/2003 |
| 6576786 | Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof The invention relates to a process for preparing substituted cyclopentane derivatives represented by the formula (I) ##STR1## wherein R1, R2, R3, R4, X and Y are as described in the specification, and pharmaceut... | 06/10/2003 |
| 6562861 | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors ##STR1## Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydroxyalkyl, ... | 05/13/2003 |
| 6531485 | Prostaglandin agonists This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for t... | 03/11/2003 |
| 6528688 | Prostacyclin derivatives An improved method is described for making 9-deoxy-PGF1 -type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.... | 03/04/2003 |
| 6512139 | Oxidation inhibitors in prostane derivatives The invention relates to the use of an oxidation inhibitor, i.e. active carbon, for ambient air in industrial manufacturing, especially in the processing of prostane derivatives, whereby the oxidation inhibitor removes ozone from the process air before co... | 01/28/2003 |
| 6495725 | Process for the preparation of optically active enones and intermediates thereof The present invention provides a simplified and convenient process for the preparation of an optically active enone such as 7,7-dimethyl-6,8-dioxabicyclo-[3,3,0]oct-3-en-2-one. The invention further provides novel optically active intermediate compounds. ... | 12/17/2002 |
| 6455584 | Prostaglandin E1 derivatives To provide a prostaglandin derivative represented by the formula: ##STR1## wherein A is an ethylene group, a vinylene group, an ethynylene group, O(CH2)q or S(O)r (CH2)q, R1 is a C3-10 | 09/24/2002 |
| 6444840 | C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R1, R2, R3, R4, R5, R6, W, ... | 09/03/2002 |
| 6441245 | Process for stereoselective synthesis of prostacyclin derivatives An improved method is described for making 9-deoxy-PGF1 -type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.... | 08/27/2002 |
| 6433014 | Compounds consisting in particular of effectors of the central nervous system receptors sensitive excitatory amino acids, preparation and biological applications The invention concerns compounds of formula (I): ##STR1## in which: R1 to R4, identical or different, represent hydrogen, alkyl or aryl, themselves substituted if required, R1 and R2 together further capable of ... | 08/13/2002 |
| 6423727 | Certain thiol inhibitors of endothelin-converting enzyme Disclosed as endothelin converting enzyme inhibitors are the compounds of the formula ##STR1## wherein the variables have the meanings as defined hereinbefore.... | 07/23/2002 |
| 6410780 | C11 oxymyl and hydroxylamino prostaglandins useful as medicaments The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R1, R2, R3, R4, R5, R6, W, ... | 06/25/2002 |
| 6410591 | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma a therapeutically effective amount of a 3, 7 or 3 and 7 thia or oxa prostanoic acid deriv... | 06/25/2002 |
| 6388128 | Stannane synthesis of prostanoids The present invention is directed to novel methods of prostanoid synthesis. Specifically, the invention is directed to the addition of alpha chains to prostanoids using cis-alkenylstannane intermediates.... | 05/14/2002 |
| 6380262 | 5-membered ring compounds ##STR1## 5-Membered ring compounds represented by general formula (I), optically active isomers thereof or salts of the same. These compounds have physiological activities including a carcinostatic effect. In said formula the bond shown by the dotted line... | 04/30/2002 |
| 6353000 | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension A method of treating glaucoma or ocular hypertension in a patient, which comprises administering to the patient a pharmaceutically effective amount of a compound of formula I: ##STR1##... | 03/05/2002 |
